These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34866584)

  • 21. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions.
    Dan K; Garcia-Garcia HM; Kolm P; Windecker S; Saito S; Kandzari DE; Waksman R
    Circ Cardiovasc Interv; 2020 Sep; 13(9):e009189. PubMed ID: 32895004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: 5-year results of the TARGET Ⅱ trial].
    Xu LJ; Gao Z; Song Y; Wang HH; Xu JJ; Gao LJ; Zhang Y; Song L; Zhao XY; Chen J; Yuan JQ; Qiao SB; Yang YJ; Xu B; Gao RL;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Jul; 46(7):523-528. PubMed ID: 30032542
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of older patients affected by coronary artery disease: results from a single-center allcomers registry.
    Buja P; Lanzellotti D; Isabella G; Napodano M; Panfili M; Favaretto E; Iliceto S; Tarantini G
    Heart Vessels; 2012 Nov; 27(6):553-8. PubMed ID: 21989862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seven-year clinical outcomes in patients undergoing percutaneous coronary intervention with biodegradable polymer coated sirolimus-eluting stent: Results from a single-center real-world experience.
    Abhyankar A; Kaul U; Sinha SK
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S280-S284. PubMed ID: 30595275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial.
    Iglesias JF; Heg D; Roffi M; Tüller D; Noble S; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Häner J; Jüni P; Windecker S; Pilgrim T
    Circ Cardiovasc Interv; 2019 Aug; 12(8):e008024. PubMed ID: 31525083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
    Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of everolimus-eluting stent length on long-term clinical outcomes of percutaneous coronary intervention.
    Yano H; Horinaka S; Ishimitsu T
    J Cardiol; 2018 May; 71(5):444-451. PubMed ID: 29174595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BIOFLOW-III satellite-One-year clinical outcomes of diabetic patients treated with a biodegradable polymer sirolimus-eluting stent and comprehensive medical surveillance.
    Kornowski R; Roguin A; Danenberg H; Assa HV; Abergel E; Rozenbaum E; Guetta V; Landes U; Jabara R; Merdler A; Segev A; Mosseri M; Assali A
    Cardiovasc Revasc Med; 2017; 18(5):338-343. PubMed ID: 28302466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year clinical outcome of percutaneous coronary intervention with very long (≥ 40mm) drug-eluting stent.
    Rajesh GN; Sulaiman S; Vellani H; Sajeev CG
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S285-S289. PubMed ID: 30595276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and effectiveness of the self-aPposing, bAlloon-delivered, siRolimus-eluting stent for the Treatment of the coronary Artery disease: SPARTA, a multicenter experience.
    Montefusco A; De Filippo O; Gili S; Mancone M; Calcagno S; Cirillo P; Esposito G; Poli A; Ferrara E; Smolka G; Wanha W; Palmieri C; Pastormerlo LE; Baumbach A; Sganzerla P; Tamburino C; Bruno F; Secco GG; Nicolino A; Yew KL; di Palma G; Wojakowski W; Sardella G; Rinaldi M; Cortese B; D'Ascenzo F
    Coron Artery Dis; 2020 Jan; 31(1):27-34. PubMed ID: 31658146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ultrathin (60 μm), ultralong (≥40 mm) sirolimus-eluting stent: study of clinical and safety profiles among real-world patients.
    Sinha SK; Aggarwal P; Pandey U; Razi M; Kumar A; Krishna V
    Anatol J Cardiol; 2021 Feb; 25(2):111-119. PubMed ID: 33583818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
    Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
    EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Outcomes of Stenting the Proximal Left Anterior Descending Artery in the PROTECT Trial.
    Roguin A; Camenzind E; Kerner A; Beyar R; Boersma E; Mauri L; Steg PG; Wijns W
    JACC Cardiovasc Interv; 2017 Mar; 10(6):548-556. PubMed ID: 28335893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.